ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells 4,082 Shares of Company Stock

ANI Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • ANI Pharmaceuticals CEO Nikhil Lalwani sold 4,082 shares for about $290,475, reducing his position by 1.23%; he retained 328,289 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
  • The company reported quarterly EPS of $2.70, beating the $2.18 consensus, while revenue of $290.78 million topped estimates and rose 27.6% year over year.
  • Analyst views were mixed: three rated the stock a Buy and four a Hold, resulting in an overall MarketBeat rating of Hold and an average price target of $100.
  • MarketBeat previews top five stocks to own in December.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 4,082 shares of the stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $71.16, for a total value of $290,475.12. Following the transaction, the chief executive officer owned 328,289 shares in the company, valued at approximately $23,361,045.24. This trade represents a 1.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

  • On Monday, November 16th, Nikhil Lalwani sold 1,318 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $71.40, for a total value of $94,105.20.
  • On Thursday, October 15th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $71.89, for a total transaction of $388,206.00.
  • On Tuesday, September 15th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $71.00, for a total transaction of $383,400.00.
  • On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $74.30, for a total value of $401,220.00.

ANI Pharmaceuticals Trading Up 2.1%

Shares of ANI Pharmaceuticals stock traded up $1.48 during trading on Wednesday, hitting $71.47. The company's stock had a trading volume of 314,389 shares, compared to its average volume of 501,263. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of 14.24, a price-to-earnings-growth ratio of 2.19 and a beta of 0.45. The stock has a 50-day moving average price of $72.32 and a two-hundred day moving average price of $76.85. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.75 and a quick ratio of 2.33. ANI Pharmaceuticals, Inc. has a 52 week low of $67.14 and a 52 week high of $87.76.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.18 by $0.52. ANI Pharmaceuticals had a net margin of 11.22% and a return on equity of 28.34%. The business had revenue of $290.78 million for the quarter, compared to analyst estimates of $280.59 million. During the same quarter in the previous year, the business earned $2.04 earnings per share. ANI Pharmaceuticals's revenue for the quarter was up 27.6% on a year-over-year basis. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price objective on the stock. Weiss Ratings restated a "hold (c+)" rating on shares of ANI Pharmaceuticals in a research note on Wednesday, November 4th. Canaccord Genuity Group decreased their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research note on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Oppenheimer assumed coverage on ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They issued a "market perform" rating and a $85.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $100.00.

View Our Latest Research Report on ANI Pharmaceuticals

Institutional Investors Weigh In On ANI Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Soleus Capital Management L.P. lifted its stake in ANI Pharmaceuticals by 12.4% in the 3rd quarter. Soleus Capital Management L.P. now owns 975,500 shares of the specialty pharmaceutical company's stock worth $70,870,000 after purchasing an additional 107,740 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of ANI Pharmaceuticals by 19.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company's stock valued at $43,399,000 after purchasing an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of ANI Pharmaceuticals by 8.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company's stock worth $40,843,000 after buying an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth $28,406,000. Finally, Aberdeen Group plc boosted its stake in ANI Pharmaceuticals by 23.0% during the third quarter. Aberdeen Group plc now owns 334,350 shares of the specialty pharmaceutical company's stock valued at $24,291,000 after buying an additional 62,590 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. Its portfolio includes products in areas such as rare disease, specialty care and established brands, alongside a range of generic drugs. The company's rare-disease portfolio includes Purified Cortrophin Gel, a prescription medicine used to treat certain inflammatory and other conditions. ANI also produces and markets complex and specialty generics, which can require more involved development or manufacturing than conventional generic drugs.

Recommended Stories

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in ANI Pharmaceuticals Right Now?

Before you consider ANI Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.

While ANI Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines